Stockwinners Market Radar for May 06, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

18:50 EDT Wheaton Precious Metals raises quarterly dividend 40% to 14c per share - Wheaton Precious Metals announced that its Board of Directors has declared its second quarterly cash dividend payment for 2021 of 14c per common share, an increase of 40% relative to the comparable period in 2020 and representing the third quarterly dividend increase in a row.

18:24 EDT Papa John's CEO: We're an e-commerce business - In an interview on CNBC's Mad Money, Rob Lynch said over 70% of the company's business comes through the e-commerce channel. Papa John's first offered digital ordering in 2001. "We've spent 20 years getting it right. We're the best at it," Lynch added. The company is working hard to make the digital experience as frictionless as possible, he noted. "We always put the best ingredients into everything we make. The creativity coming from our culinary group is amazing," Lynch said.

18:03 EDT Southside Bancshares increases quarterly cash dividend 3.1% to 33c per share - The board of directors of Southside Bancshares approved a 3.1% increase to the regular quarterly cash dividend of 1c to 33c per common share and declared a regular quarterly cash dividend of $0.33 per common share. The cash dividend is scheduled for payment on June 3 to common stock shareholders of record on May 20.

17:57 EDT Fox Factory appoints Toby Merchant Chief Legal Officer - Fox Factory has announced the appointment of three key new leadership additions as the Company continues to lay the foundation for its next phase of growth. "Thanks to our existing team, we have experienced tremendous growth and portfolio diversification. In order to achieve the breakthrough results we aspire to reach, we have to do things thoughtfully and with our strategic vision in mind," commented Mike Dennison, FOX's Chief Executive Officer.Mr. Toby D. Merchant joins the Company as its first Chief Legal Officer and Secretary. Mr. Merchant has over 16 years of experience working with public and private companies on a variety of matters ranging from corporate governance, securities matters, and company-specific issues, to leading domestic and international mergers, acquisitions, and divestitures. Prior to joining the Company, Mr. Merchant was the Chief Operating Officer and General Counsel to McKenna & Associates,a boutique advisory firm that manages its own proprietary capital. Before that, Mr. Merchant was a partner at Squire Patton Boggs where he was a member of the firm's global Corporate and Financial Services practice groups from October 2006 until November 2019. Prior to Squire Patton Boggs LLP, Mr. Merchant was an associate at Dinsmore & Shohl LLP in the firm's corporate practice group. Mr. Merchant graduated with a B.S. degree from Cornell University and earned his Juris Doctor at Case Western Reserve University where he graduated cum laude. Chief Purpose & Inclusion Officer Additionally, the Company recently promoted Ms. Jackie B. Martin to Chief Purpose & Inclusion Officer. She joined the Company in September 2020 as Vice President, Inclusion, Diversity & Engagement.

17:55 EDT CACI awarded $496M Air Force contract for ATSSI II - CACI has been awarded an estimated maximum $496M indefinite-delivery/indefinite-quantity contract for Automated Test System Sustainment Initiative II, or ATSSI II. This contract provides support to the Ogden Air Logistics Complex's, or OO-ALC, ATSSI II program for the continued development and sustainment of a depot technology infrastructure supportive of the OO-ALC mission to perform critical test functions important to the ongoing operational safety, suitability, and effectiveness of multiple Air Force weapon systems/subsystems. Work will be performed at Hill Air Force Base, Utah, and is expected to be completed May 5, 2030. This award is the result of a competitive acquisition and two offers were received. FY21 working capital funds in the amount of $266,679 are being obligated on the first task order. Air Force Sustainment Center is the contracting activity.

17:44 EDT iBio provides update on its IBIO-201 program - iBio provided an update on its IBIO-201 program and reported on its progress in developing a second-generation subunit vaccine candidate, IBIO-202, being designed for the prevention of SARS-CoV-2 infection. IBIO-201, the Company's vaccine candidate combining antigens derived from the spike protein fused with iBio's patented LicKM booster molecule, recently completed IND-enabling toxicology studies. The studies identified no adverse effects at low or high doses. -"Combined with data from previous immune-response studies, these pathology results help demonstrate the potential value of LicKM as a useful tool in our vaccine development toolbox," said Tom Isett, Chairman and CEO of iBio. The Company also reported on development of IBIO-202, a subunit vaccine candidate that targets the nucleocapsid protein ( of SARS-CoV-2. N proteins of many coronaviruses are highly immunogenic and are expressed abundantly during infection. In addition, the N protein is more highly conserved than the S protein, and therefore new viral variants may be less likely to escape vaccine protection.

17:34 EDT Montauk Renewables signs agreement to sell RNG for European market use - Montauk Renewables announced that it has signed an agreement to sell a portion of its Renewable Natural Gas, or RNG, production as a feedstock to make fuel for the European market. Beginning July 2021, the company will sell approximately 900,000 MMBtu annually of is production, currently monetized under an expiring domestic floor-price agreement, to Iogen RC Fuels under a new 4.5 year fixed-price agreement to make vehicle fuel to serve the European market.

17:31 EDT Peloton rises over 1% to nearly $85 during quarterly call

17:26 EDT Beyond Meat sees continued sequential improvement in food services business - Sees year-over-year growth in sales for food service customers.

17:20 EDT EOG Resources lowers 2021 crude oil volume view to 433,000-444,000 Bopd - Sees 2021 natural gas volumes 1,295-1,445 MMcfd.

17:18 EDT Beyond Meat sees unveiling new lower fat Beyond Burger patty later this year - Says seeing enough stability in recent trends to cautiously resume near-term guidance. Says providing guidance with the understanding that a resurgence of COVID-19 would cause company to revisit guidance. Says saw continued momentum in international retail. Says Beyond Burger rated #1 plant-based burger in Germany by large consumer advocacy group. Says U.S. food service revenue slipped as business continues to grapple with slowing demand due to COVID-19. Sees introducing second Beyond Burger patty option with less saturated fat later this year. Comments taken from Q1 earnings conference call.

17:17 EDT Peloton to postpone launch of Tread in the U.S. - Says Tread, the company's treadmill, was originally set to come out May 27. Says will continue to produce treadmill content. Says there have been reports of minor quality issues related to how tablet console is attached to the Tread. Sees offering Tread for sale as soon as CPSC's full review is completed. Comments taken from Q3 earnings call.

17:12 EDT Dropbox Q1 ARR increased 13% - The company states: "Total ARR ended at $2.112B, an increase of 13% from the same period last year. On a constant currency basis, Total ARR grew $60.5M quarter-over-quarter, and year-over-year growth would have been 12%. Paying users ended at 15.83M, as compared to 14.59M for the same period last year. Average revenue per paying user was $132.55, as compared to $126.30 for the same period last year."

17:03 EDT Standard Financial, Dollar Mutual Bancorp approved for merger - Dollar Mutual Bancorp and Standard AVB Financial jointly announced that the parties have received all the regulatory approvals necessary to complete the merger of Standard into Dollar. The Standard stockholders approved the merger at a special meeting of stockholders held on January 19. The parties expect that their proposed merger transaction will be completed after market hours on May 28. Dollar is the mutual holding company for Dollar Bank, Federal Savings Bank. Standard is the stock holding company of Standard Bank, PaSB, a Pennsylvania chartered savings bank. In connection with the merger of Standard into Dollar, Standard Bank will convert to a federal savings bank. Dollar Bank and Standard Bank will continue to operate as separate financial institutions with Dollar as the holding company for each institution.

16:58 EDT DiamondRock sells Frenchman's Reef resort to Fortress affiliate - DiamondRock Hospitality Company announced that it sold the 478-room Frenchman's Reef Marriott Resort & Spa and Noni Beach, Autograph Collection project in St. Thomas, U.S.V.I. to an affiliate of Fortress Investment Group LLC. As consideration, DiamondRock has received an upfront cash payment as well as a participation right in the future profits of the hotel once certain return metrics are achieved. The resort has been closed since it experienced devastating impact from sequential hurricanes in 2017. Under Fortress ownership, the Frenchman's Reef will complete a major rebuilding project and reopen as a global destination resort. "We are extremely excited to steward this important property through the completion of its ambitious rebuilding and, ultimately, to its reopening as a global destination with unrivaled facilities and amenities," said Thomas W. Pulley, Global Head of the Fortress Credit Real Estate business. "This is a remarkable property-an irreplaceable asset that we are thrilled to add to our portfolio. We welcome the opportunity to contribute to the long-term vibrancy of the St. Thomas economy, and look forward to working closely with U.S.V.I. officials and engaging with the people of St. Thomas as an important employer."

16:57 EDT Datadog names Adam Blitzer as COO, effective May 10 - Datadog (DDOG) announced the appointment of Adam Blitzer as COO. Blitzer brings fourteen years of experience in the SaaS space. Blitzer was at Salesforce (CRM) for eight years, culminating in his role as Executive Vice President and General Manager of Digital. Blitzer will join Datadog on Monday, May 10.

16:52 EDT Materion raises quarterly dividend to 12c from 11.5c per share - The dividend is payable on June 11, 2021 to shareholders of record at the close of business on May 27, 2021.

16:52 EDT Expedia seeing booking trends well above 2019 levels

16:48 EDT Expedia cautiously optimistic about pace, shape of recovery

16:46 EDT Expedia remains on track for $200M in annual savings

16:44 EDT Expedia: Summer looks 'strong,' particularly in the U.S. - Says summer looks strong particularly in the U.S., where vaccinations are well along the way. Comments taken from Q1 earnings conference call.

16:41 EDT Dicerna sees cash sufficient to fund clinical, operating plan into 2024 - Dicerna believes that its cash, cash equivalents, held-to-maturity investments, the proceeds from the April 2021 royalty financing transaction and anticipated milestone and other payments from existing collaborations will be sufficient to fund the execution of its current clinical and operating plan into 2024, which includes the Company's expectations to advance nedosiran through planned pivotal development, regulatory filing and approval and commercial launch; and supporting all R&D activities for current internal and collaboration pipeline programs. This estimate assumes no funding from new collaboration agreements or from external financing events and no significant unanticipated changes in costs and expenses. Dicerna expects its overall expenses to continue to increase for the foreseeable future, largely due to investments in staffing and market readiness activities, clinical manufacturing activities, continued clinical activities associated with its core product candidates and continued activities under its existing collaboration agreements. The Company continues to forecast receiving over $83 million in cash from its current collaboration agreements during full-year 2021.

16:40 EDT Texas Pacific Land board approves $20M share repurchase program - The company said: "On May 3, 2021, our board of directors approved a stock repurchase program to purchase up to an aggregate of $20.0 million of shares of our outstanding common stock."

16:35 EDT Orion Engineered sees FY21 adjusted EBITDA $250M-$280M - "Despite the still challenging COVID-19 situation in many countries, our second quarter order book remains strong and we are confident in our ability to navigate 2021 and beyond successfully. Although our customers' visibility into the second half is less clear than usual, we are reinstating full year 2021 Adjusted EBITDA guidance in the range of $250 million to $280 million," the company said.

16:33 EDT Ryder names John Diez CFO - Ryder System announced the appointment of John J. Diez to executive vice president and chief financial officer. Mr. Diez succeeds Scott T. Parker, who resigned from his position to pursue other opportunities and will remain with Ryder through June 4, 2021 to ensure a smooth transition. Diez, most recently president of Ryder's Fleet Management Solutions (FMS) business, will oversee all of Ryder's financial management functions including finance and accounting, treasury, tax, audit, corporate strategy, and investor relations. As part of this organizational change, Tom Havens, most recently senior vice president and global chief of operations for the FMS business since 2012, has been named president of Ryder's FMS business unit. With this promotion, Mr. Havens joins Ryder's executive leadership team and reports to Ryder Chairman and Chief Executive Officer Robert E. Sanchez.

16:29 EDT Eventbrite says gross margins expected to improve - The company states: "As we prepare to move beyond the pandemic and into the future, the structural improvements made to Eventbrite's operating and financial model are becoming ingrained and increasingly evident. Self-sign-on creators accounted for two-thirds of paid tickets in the first quarter, up from one-half a year ago, as we increased emphasis on our most profitable acquisition channel. We acquired over 75,000 new creators during the first quarter without making any upfront incentive payments, and the proportion of first quarter ticket sale proceeds advanced to creators was reduced by 91% compared with a year ago, reflecting the less capital intensive, lower risk nature of self-service customers and changes to our advance payment program. The shift in strategy to focus more on further developing and differentiating our self-service capabilities and less on delivering high-touch support services positions Eventbrite well as the market recovers. Gross margins are poised to improve with increasing paid ticket volume and the discontinuation of certain lower-margined services offered previously. As intended, Sales and Marketing expenses and General and Administrative expenses eliminated in April 2020 have not returned, and we've continued to invest first and foremost in Product and Engineering to support creators' needs. The significant expense reductions we implemented one year ago increase operating leverage, lower our breakeven and provide a path to profitability on an adjusted EBITDA basis as the year and the recovery progress."

16:22 EDT Telephone and Data raises 2021 revenue view to $3.05B-$3.15B from $3.03B-$3.13B - Raises 2021 adjusted EBITDA view to $1.03B-$1.13B from $975-$1.13B. Sees 2021 Capital expenditures $775M-$875M.

16:20 EDT Unisys reports total company backlog of $3.4B vs. $3.6B as of 4Q20

16:17 EDT Square says Seller GPV up 144% year over year in April - Square said: "Given the uncertainty around the impact and severity of COVID-19, we wanted to provide an update on the trends in our business during the month of April... In April, Seller delivered strong gross profit growth year over year. Seller GPV was up 144% year over year in April. The two-year compound annual growth rate for Seller GPV in April was 21%, which was relatively consistent with March. In April, GPV growth improved compared to year-over-year results in the first quarter, driven primarily by regional reopenings, government fund disbursements, and lapping the impact of COVID-19 starting in late March of 2020. We saw continued strength in GPV from our online channels as well as an improvement in in-person activity, which benefited from regional reopenings. GPV growth trends continued to vary by region, product, and vertical, depending primarily on differences in the timing and phases of reopenings."

16:15 EDT TripAdvisor: March monthly unique users 58% of 2019's comparable period - January, February, and March 2021 monthly unique users on Tripadvisor-branded websites improved sequentially and were approximately 53%, 56%, and 58%, respectively, of 2019's comparable period, driven by vaccine progress and leisure travel's improving recovery, particularly in the U.S. The company notes that U.S. monthly unique users in March 2021 approached nearly 80% of 2019 levels while traffic outside the U.S. was approximately half of 2019 levels for the same period.

16:13 EDT Bill.com to buy Divvy in stock and cash deal valued at $2.5B - Bill.com announced it has entered into a definitive agreement to acquire Divvy in a stock and cash transaction valued at approximately $2.5B. The transaction has been approved by the Boards of Directors of both Divvy and Bill.com. The deal is expected to close by the end of Bill.com's first fiscal quarter ending September 30, 2021, and is subject to receipt of regulatory approvals and other customary closing conditions. Bill.com will acquire Divvy for approximately $625M in cash and $1.875B of Bill.com Common Stock, subject to customary adjustments for transactions of this nature. "Divvy is a leader in spend management that modernizes finance for business by combining expense management software and smart corporate cards into a single platform. The acquisition supports Bill.com's mission and enhances our ability to deliver value to the combined customer base. Bill.com's expanded solution will enable businesses to automatically manage accounts payable, accounts receivable, and corporate card spend all in one place, saving them valuable time and money. With real-time insight into all their B2B spending and access to multiple payment solutions, businesses will be empowered to spend smarter, better manage their budgets and cash flow, and simplify their back-office financial operations," the company said.

16:09 EDT GoPro subscribers surpassed 1M in April

16:06 EDT ChromaDex sees continued gross margin improvement to slightly over 60% - Looking forward, for the full year, the company expects continued, steady revenue growth driven by its global ecommerce business, as well as growth with existing and new strategic partners, and that the growth rate will accelerate beginning in the second quarter. The company expects continued gross margin improvement to slightly better than 60%, roughly flat R&D expense and slightly higher selling and marketing expense as a percentage of net sales year-over-year. The Company expects slightly higher general and administrative expense, excluding severance, restructuring and legal expense. The company plans to increase investments and resources to drive brand awareness and accelerate its R&D pipeline to capitalize on growth in the NAD+ market globally.

16:05 EDT Cytokinetics sees revising financial guidance mid-year - "We expect to revise our financial guidance mid-year once we finalize strategies and potential commercial launch plans for omecamtiv mecarbil. Executing on those strategies and plans may result in our incurring significant additional expenses that were not included in our current financial guidance. We expect that some or all of those potential expenses could be covered by our accessing additional capital through strategic partnership(s) with near term cash infusions or by equity and/or debt financings if deemed appropriate," the company said in a statement

15:17 EDT Americold Realty Trust trading halted, news pending

14:52 EDT Massachusetts AG sues Publicis over opioid marketing schemes - Massachusetts Attorney General Maura Healey filed a lawsuit against Publicis Health alleging it designed and deployed unfair and deceptive marketing schemes to help Purdue Pharma sell more OxyContin, including in Massachusetts. In a complaint filed in Suffolk Superior Court today, AG Healey alleges that from 2010 to 2019, Publicis - a subsidiary of global advertising conglomerate Publicis Groupe - partnered with Purdue on dozens of contracts, collecting more than $50M in exchange for marketing schemes to get doctors to prescribe Purdue's opioids to more patients, in higher doses, for longer periods of time. "Responsibility for the opioid crisis runs across the industry, from Purdue and the Sacklers, to consultants and partners like McKinsey and Publicis," said AG Healey. "Publicis convinced doctors to prescribe more OxyContin to more patients as the opioid epidemic was raging. As a result, patients in Massachusetts suffered, overdosed, and died, while Publicis collected tens of millions of dollars." Reference Link

14:33 EDT Ambac Financial trading resumes

14:06 EDT Ambac Financial trading halted, news pending

13:40 EDT Aeva Technologies reports 'beyond 500m detection range' for 4D LiDAR - Earlier, Aeva Technologies announced that its "industry-first" 4D LiDAR "now delivers beyond 500m detection range, significantly enhancing its previous performance with software improvements on existing hardware." Mina Rezk, Co-founder and CTO of Aeva, said: "Our team continues to push the boundaries of what's possible toward creating the best perception solution that is built on Aeva's breakthrough FMCW 4D LiDAR on-chip technology, as we aim to offer a combination of performance and scalability that we believe to be unmatched in the industry. This is all accomplished using Aeva's current 4D LiDAR hardware, providing a glimpse of the continuous improvements we aim to deliver to our customers through our proprietary FMCW technology and over-the-air software updates."

13:31 EDT Google Assistant reveals new family features ahead of Mother's Day - Lilian Rincon, Senior Director of Product Management, Google Assistant, wrote in in part earlier on The Keyword blog: "Moms everywhere can likely agree that this year (and then some) has had us working overtime...We're extending one of our most popular Assistant features, Broadcast, so you can reach your family wherever they are, and they can respond from any device including from their phones. With Family Broadcast, when I get home from my Saturday morning run, I can broadcast to my newly created Google Family Group, "Hey Google, tell my family, how about lunch at noon?" ...Two new Family Bell reminders I plan to set this weekend will remind me to water the plants (which I love, but often forget to do) as well as alert my kids to tidy up the house. It's becoming a very popular feature. Since last summer, more than 20 million Family Bells have been rung to help families stay organized - that's nearly 19 years worth of bells! As a quick hint, you'll soon be able to just say "stop" to end the bell, starting in English. No need to use "Hey Google" again, just like with alarm and timers...Assistant is getting new stories and games that you can access from a smart display or Android device - this weekend, we plan to learn more about Quidditch from the Harry Potter stories with a simple "Hey Google, tell me a Quidditch Story." ...Hopefully this schedule gives you a little Mother's Day inspiration - or even just a stress-free weekend." Reference Link

13:00 EDT Glatfelter raises quarterly dividend 3.7% to 14c per common share - Glatfelter announced that its board of directors declared a 14c per share cash dividend on its outstanding common stock. The new dividend amount represents a 3.7% increase compared to the prior quarterly amount. The dividend is payable on August 2 to all shareholders of record as of the close of business on July 1.

12:44 EDT Ubisoft announces free-to-play game 'Tom Clancy's The Division Heartland' - Ubisoft announced new video game "Tom Clancy's The Division Heartland," a free-to-play game set in "The Division" universe, is in development at the company's Red Storm studio. "Heartland" is a standalone game that doesn't require previous experience with the series but will provide an all new perspective on the universe in a new setting. The game will be made available in 2021-22 on PC, consoles, and cloud. "The Division" will also be coming to mobile platforms for the very first time, Ubisoft said. Reference Link

12:25 EDT Mohawk Industries exec Thiers sells 5,000 common shares - In a regulatory filing, Mohawk Industries' president of Flooring ROW Bernard Thiers disclosed the sale of 5,000 common shares of the company on May 5 at a price of $222 per share.

12:01 EDT Quotient Technology falls -22.3% - Quotient Technology is down -22.3%, or -$3.76 to $13.11.

12:01 EDT Fastly falls -25.0% - Fastly is down -25.0%, or -$14.52 to $43.54.

12:00 EDT At Home Group rises 16.7% - At Home Group is up 16.7%, or $5.22 to $36.51.

11:59 EDT Google to soon automatically enroll users in two-step verification - In a blog post, Google provided a "sneak peek" at its new investment in tools and features to protect user information, including passwords, and is aiming to create a future where people "won't need a password at all." "Today we ask people who have enrolled in two-step verification (2SV) to confirm it's really them with a simple tap via a Google prompt on their phone whenever they sign in," the company said. "Soon we'll start automatically enrolling users in 2SV if their accounts are appropriately configured. (You can check the status of your account in our Security Checkup). Using their mobile device to sign in gives people a safer and more secure authentication experience than passwords alone. We are also building advanced security technologies into devices to make this multi-factor authentication seamless and even more secure than a password. For example, we've built our security keys directly into Android devices, and launched our Google Smart Lock app for iOS, so now people can use their phones as their secondary form of authentication." Reference Link

11:08 EDT Caesars, Arizona Diamondbacks team up for mobile sports betting - Caesars Entertainment announced a partnership with the Arizona Diamondbacks to launch mobile sports betting in Arizona and build a sportsbook and bar concept on the plaza adjacent to the team's home, Chase Field. The deal simultaneously grants Caesars Entertainment mobile sports betting market access and exclusive sponsorship in sports betting and daily fantasy sports for the D-backs. In tandem, Caesars also finalized a multi-year agreement with Major League Baseball to become an Authorized Gaming Operator of the league.

10:53 EDT Adtran sees Q2 non-Gaap OpEx about $52M-$53M

10:44 EDT Tuesday Morning appoints Fred Hand as CEO, member of board of directors - Tuesday Morning (TUEM) announced that Fred Hand has been named Chief Executive Officer and a member of the board of directors, effective May 17. Hand most recently served as Chief Operating Officer of Burlington Stores (BURL). Hand's appointment follows the previously announced transition of Steven Becker, who will step down from his role as CEO and director. Becker will continue to serve in a consultancy role until September 30, 2021.

10:23 EDT Falcon Minerals declares Q1 dividend of 10c per share, up 33% from Q4 - Falcon's board of directors declared a dividend of 10c per Class A share for the first quarter 2021, which will be paid on June 8 to all Class A shareholders of record on May 25. The dividend represents a 33% increase from fourth quarter 2020, Falcon Minerals noted in its Q1 earnings release last night. "The first quarter 2021 dividend does not have any effect on the current $11.34 exercise price of the company's outstanding warrants. The company expects that greater than 50% of its 2021 dividends will not constitute taxable dividend income and instead will result in a non-taxable reduction to the tax basis of the shareholders' common stock. The reduced tax basis will increase a shareholders' capital gain, or decrease shareholders' capital loss, when shareholders' sell their common stock," Falcon stated.

10:03 EDT At Home Group trading resumes

10:00 EDT Quotient Technology falls -18.1% - Quotient Technology is down -18.1%, or -$3.06 to $13.81.

10:00 EDT Acushnet Holdings rises 12.4% - Acushnet Holdings is up 12.4%, or $5.32 to $48.23.

10:00 EDT Sally Beauty rises 19.2% - Sally Beauty is up 19.2%, or $3.90 to $24.16.

09:49 EDT At Home Group to be acquired by Hellman & Friedman for $2.8B, $36 per share - At Home Group announced that it has entered into a definitive agreement to be acquired by funds affiliated with Hellman & Friedman in an all-cash transaction valued at $2.8 B, including the assumption of debt. Under the terms of the agreement, At Home stockholders will receive $36.00 per share in cash, which represents a premium of approximately 17% to the company's closing stock price of $30.67 on May 4, 2021, the last trading day prior to media speculation regarding a possible transaction, and a premium of approximately 25% to the 30-day volume weighted average share price. The transaction was negotiated on behalf of At Home by a Special Committee of its board of directors composed entirely of independent directors with the assistance of independent financial and legal advisors. Following the Special Committee's unanimous recommendation, At Home's Board of Directors unanimously approved the merger agreement and has recommended that At Home's stockholders adopt and approve the merger agreement and the transaction. The transaction is expected to close in Q3 of calendar year 2021, subject to the satisfaction of customary closing conditions, including the approval of At Home's stockholders and expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The transaction is not subject to a financing condition. Upon completion of the transaction, At Home will become a privately-held company and At Home's shares will no longer trade on The New York Stock Exchange.

09:47 EDT Regis falls -14.5% - Regis is down -14.5%, or -$1.74 to $10.30.

09:47 EDT Quotient Technology falls -18.9% - Quotient Technology is down -18.9%, or -$3.19 to $13.68.

09:47 EDT Acushnet Holdings rises 14.7% - Acushnet Holdings is up 14.7%, or $6.30 to $49.21.

09:46 EDT At Home Group to be acquired by Hellman & Friedman for $36 per share

09:45 EDT Aptorum Group, Exeltis to develop preclinical candidate for endometriosis - Aptorum Group has entered into an agreement with Exeltis to develop, manufacture and commercialize a novel preclinical candidate from Aptorum in the following territories: the European Union and Latin America. This novel candidate is intended to target woman's health and gynecological conditions, such as endometriosis or related conditions. Under the agreement, Aptorum Group will retain the development rights in other jurisdictions in the world, as well as the right to develop the novel candidate into a drug product. Commercialization of the product is subject to relevant regulatory approvals in their respective jurisdictions.

09:42 EDT At Home Group trading halted, news pending

09:38 EDT Kellogg says continues to grow rapidly in e-commerce - Says gained share in most key markets around the world in Q1. Says cash flows remain strong. Comments taken from Q1 earnings conference call.

09:34 EDT Benefitfocus says ADP seeks injunction from court barring Levin's employment - In a regulatory filing, Benefitfocus (BNFT) disclosed that on May 3, a complaint was filed against Matthew Levin by his former employer, ADP, Inc. (ADP), followed on May 5, 2021 by an application for a temporary restraining order and preliminary injunction in the United States District Court for the District of New Jersey. The ADP complaints allege that Mr. Levin, the recently appointed President and CEO of Benefitfocus, in beginning employment with the company would be in violation of restrictive covenant agreements he entered into with ADP while he was employed as its Chief Strategy Officer. The ADP complaints request, among other things, an injunction from the court barring Mr. Levin's employment with the company. "The company believes the claims made in the ADP complaints are without merit and Mr. Levin intends to vigorously defend himself against these actions and begin his employment with the company as planned on May 10," Benefitfocus stated in the filing.

09:32 EDT ADT trading halted, volatility trading pause

09:30 EDT Euroseas announces charter for M/V 'EM Hydra' - Euroseas announced a new time charter contract for its container vessel M/V "EM Hydra". Specifically: M/V "EM Hydra", a 1,740 TEU vessel built in 2005, entered into a new time charter contract for a period between a minimum of twenty three and a maximum of twenty five months at the option of the charterer, at a gross daily rate of $20,000. The new rate will commence between May 15, 2021 and May 25, 2021 when the vessel will be redelivered from its current charterer.

09:28 EDT PureCycle sinks after called 'ESG SPAC charade' by short-seller Hindenburg - Shares of PureCycle Technologies are down $5.88, or 24%, to $18.71 in pre-market trading after short selling research firm Hindenburg Research called the company a "zero-revenue ESG SPAC charade" in a report published this morning on its website. PureCycle's Chairman/CEO and other associated executives "collectively took 6 companies public prior to PureCycle. All have failed, resulting in 2 bankruptcies, 3 delistings, and 1 acquisition after a ~95% decline," said Hindenburg, which claims that former employees of earlier "failed companies" said PureCycle's executives "based their financial projections on 'wild ass guessing', brought companies public far too early, and had deceived investors." Multiple competitors and industry experts argue that PureCycle "faces steep competition for high quality feedstock, and called the company's financial projections into question," according to Hindenburg. Reference Link

09:24 EDT SS&C further increases offer on acquisition of Mainstream Group - SS&C has amended the Scheme Implementation Deed with Mainstream Group to provide for an acquisition by SS&C of 100% of the shares and outstanding equity rights in Mainstream for A$2.56 per security pursuant to a scheme of arrangement. In the absence of a superior proposal, and subject to the independent expert recommendation, the board of directors of Mainstream intends to support the revised scheme of arrangement on that basis. Terms of the proposed acquisition imply an enterprise value for Mainstream of approximately A$376M or approximately $290M. The purchase is expected to close in Q3. Mainstream has subsequently received a further unsolicited proposal from the same third party at AUS$2.60 per share in cash. Mainstream is currently considering the proposal and may determine that it is a superior proposal, but has not yet done so. If Mainstream does determine that it is a superior proposal, SS&C will have 4 business days to match or offer more favorable terms to the third party's further unsolicited proposal.

09:23 EDT Ironwood announces up to $150M share repurchase program - Ironwood announced that its board of directors has authorized a new share repurchase program under which the company may repurchase up to $150M of its outstanding shares of common stock through December.

09:18 EDT CN moved 2.9 MMT of western Canadian grain in April - CN announced that it moved 2.90 million metric tonnes of western Canadian grain in April 2021, exceeding the previous April record of 2.82 MMT set in 2020 and over 5% ahead of the three-year average of 2.75 MMT. So far, during the 2020-2021 crop year, CN has moved over 25.6 MMT of Canadian grain via carload. This is an increase of 17% compared to the previous crop year to-date record of 21.9 MMT established in the 2018-19 crop year. Containerized grain shipments direct from western Canada are also on record pace at over 860,000 metric tonnes shipped crop year to-date, in addition to the tonnage shipped from eastern Canada.

09:18 EDT Greenlight's Einhorn says AerCap continues track record of 'attractive' deals - David Einhorn, Chairman of Greenlight Capital Re, is speaking about the firm's long positions in AerCap (AER) and Danimer Scientific (DNMR) on the company's earnings call. Danimer's intellectual property is "extremely valuable," criticism on the biodegradability of its products is "unfounded" and recent short reports on the company have included a "blatant misuse of data," Einhorn says.

09:17 EDT ViacomCBS says advertising revenue continues to improve - Expects double digit advertising growth in Q2 Expects continued robust streaming growth in Q2. Says "well-positioned" to take share in streaming market. Says "super excited" about Paramount+ trends.

09:15 EDT Luokung Technology allowed to resume trading on Nasdaq - Luokung Technology's motion for a preliminary injunction was granted by the U.S. District Court for the District of Columbia, and that as a result of the ruling, the Department of Defense and other government defendants are enjoined from implementing or enforcing the designation of Luokung as a Communist Chinese military company, and the resulting restrictions pursuant to Executive Order 13959. Upon receipt of the Court's decision, Luokung contacted Nasdaq and requested that Nasdaq reconsider the delisting determination that it previously issued. Nasdaq has withdrawn its delisting letter, and the company's shares will continue to trade on the NASDAQ stock market.

09:14 EDT Seanergy Marine announces delivery of M/V Hellasship, time charter with NYK Line - Seanergy Maritime announced that it has taken delivery of the 181,325 dwt Capesize bulk carrier, built in 2012 by Imabari Shipbuilding. in Japan, which was renamed M/V Hellasship. The delivery of the M/V Hellasship is the first of the four Capesize acquisitions performed already in 2021. The Vessel has been fixed on a time charter with NYK Line, a leading Japanese shipping company and operator. The T/C is expected to commence immediately, upon finalization of the customary transition process and will have a term of minimum 11 to maximum 15 months from the delivery. The gross daily rate of the T/C is based at a premium over the Baltic Capesize Index.

09:12 EDT Abbott begins trial for combined atrial fibrillation and heart failure treatment - Abbott announced a new trial focused on treatment for people simultaneously battling both atrial fibrillation and heart failure. The first-of-its-kind trial aims to provide new insights into more effective treatment for patients with AFib and heart failure. Clinical trials assessing therapies deployed in tandem to manage cardiovascular comorbidities are rare. For patients, the two conditions increase the risk of stroke, hospitalization or even death. The TAP-CHF trial will manage patients in two phases to better help physicians understand the impact of monitoring fluctuations in pulmonary pressure. Abbott expects the TAP-CHF trial to enroll up to 100 patients at 10 trial sites in the U.S. At the end of the trial, outcomes of patients who had their heart failure management guided by data from the CardioMEMS HF System will be compared to those who received standard of care (medicine) for their heart failure to determine which patient group had better outcomes based on recurrence of AFib, hospitalization or death. The trial will also provide insights into the effect of catheter ablation in patients with HFpEF.

09:10 EDT Omniq to acquire Dangot Computers for $7.6M - OMNIQ announced that it has entered into a definitive acquisition agreement pursuant to which OMNIQ will acquire 51% of Dangot Computers, "a leader in providing state of the art technology enabling frictionless automated order processing & digital payment processing products for retail, fast food and parking, integrated working stations for physicians, drug delivery and blood tests, robotics for smart warehouses, point of sales and other innovative solutions." Upon the effectiveness of the acquisition, OMNIQ will pay the shareholder of Dangot a total of approximately $7.6 million comprised of approximately $5.6 million to be paid in cash and $2 million in restricted shares based on average closing share price over the 30 trading days prior to signing. OMNIQ will have a one-year option to acquire the remaining 49% at the same valuation. Closing is expected shortly, upon receipt of approval by the Israeli Competition Authority.

09:08 EDT AbCellera teams with Angios to develop therapeutics to combat blindness - AbCellera and Angios GmbH announced that they have entered into a multi-year, multi-target collaboration to facilitate the discovery of monoclonal and bispecific antibodies for vascular diseases of the eye. AbCellera will use its full stack, AI-powered antibody discovery platform to generate panels of antibodies for up to three Angios-selected targets to address diabetic retinopathy. "Through this collaboration, Angios can focus on advancing their unique scientific insights for treating blindness in diabetes, rather than on establishing and scaling internal antibody discovery capabilities," said Carl Hansen, Ph.D., CEO and President of AbCellera. "We are excited to work closely with Angios to start their programs without delay, including identifying bispecific antibodies against diabetic retinopathy, and moving them forward at maximum speed." Diabetic retinopathy, which is a complication of type 1 and 2 diabetes, is caused by chronic hyperglycemia and is the leading cause of preventable visual impairment and blindness in working-age adults. Patients with diabetes who have an increased risk of developing retinopathy include those with comorbid hypertension and dyslipidemia.1,2

09:08 EDT One Medical, ParetoHealth partner to provide healthcare to employers - One Medical and ParetoHealth announced a national distribution partnership to offer One Medical's primary care to ParetoHealth's customer base of over 1,400 employers with more than 440,000 lives covered nationwide. "Together, the two organizations aim to improve employee well-being with a highly engaging healthcare benefit that supports employers in taking control of healthcare costs," the company said. "We believe the combination of One Medical and ParetoHealth's products can provide benefits to employers and employees that are unmatched in the industry. No one else has enhanced primary care and virtual care partnered with a self-insurance solution offering multiyear protection and integrated cost management," said Andrew Cavenagh, CEO, ParetoHealth. "Access to high-quality primary care not only reduces the frequency and severity of high-cost medical claims, but the cost of healthcare overall. It allows employers to guide employees to better quality, lower cost healthcare while providing them with much-needed transparency into healthcare needs in their organization. By partnering with One Medical, ParetoHealth is able to offer our members a unique primary care solution on a national level."

09:07 EDT Novavax finalizes advance purchase agreement with Gavi - Novavax announced that it has finalized an advance purchase agreement with Gavi, the Vaccine Alliance, for supply of its recombinant protein-based COVID-19 vaccine candidate to the COVAX Facility. Under the APA, Novavax is expected to manufacture and distribute 350M doses of NVX-CoV2373 to countries participating under the COVAX Facility, which was established to allocate and distribute vaccines equitably to participating countries and economies. Under a separate purchase agreement with Gavi, the Serum Institute of India is expected to manufacture and deliver the balance of the 1.1B doses of Novavax' vaccine. Under the APA, Novavax expects to deliver doses with antigen and adjuvant manufactured at facilities directly funded by the investments Novavax received from the Coalition for Epidemic Preparedness Innovations. CEPI invested nearly $400M in Novavax in the spring of 2020 to advance preclinical and early clinical development, manufacturing scale-up, technology transfer, and manufacturing capacity reservation for NVX-CoV2373. Together, Novavax and Serum Institute expect to initiate delivery of the cumulative 1.1B doses in the third quarter of 2021, pending receipt of appropriate regulatory authorizations. Under the APA, Novavax will receive an upfront payment from Gavi later this month and an additional payment after it secures Emergency Use Listing for its vaccine by the WHO. In addition, Novavax has agreed to provide additional doses in the event that Serum Institute cannot materially deliver expected vaccine doses to the COVAX Facility. Vaccine dose allocation will be determined by Gavi across the AMC-eligible and self-financing participants under a tiered pricing schedule.

09:06 EDT Container Store partners with Instacart for same-day delivery nationwide - The Container Store and online grocery platform Instacart announced a new national partnership, which will offer customers same-day delivery }from all 93 The Container Store locations. The new partnership has kicked off across Texas, with plans to expand nationwide across 33 states and Washington D.C. in the coming weeks.

09:05 EDT Flushing Financial participating in FHLBNY Small Business Recovery Grant Program - Flushing Financial Corporation announced that the Bank is once again participating in the FHLBNY Small Business Recovery Grant Program. This program supports the financial security and health of workers employed by organizations that have suffered a decrease in revenue as a result of the ongoing COVID-19 crisis.

09:04 EDT Daxor receives NIH funding notification for trial using BVA-100 - Daxor announces the initiation of a multi-center clinical trial with two Veterans Affairs Medical Centers to evaluate Blood Volume Analysis guided management of acute decompensated heart failure utilizing the BVA-100 blood test. "We are gratified to have received notification of intent to fund the study from the NIH so that work may commence immediately with the VA system for this landmark prospective study. Past published data has shown BVA-100 guided care has led to reductions in patient mortality of over 82% and 56% for readmissions. This grant and potential subsequent funding stages will result in the highest quality of clinical data driving adoption of Daxor's unique technology broadly, as well as validation of Daxor's patent-pending clinical guidance system", said Michael Feldschuh, CEO and President of Daxor. "High rates of heart failure rehospitalization and mortality and high treatment costs have persisted for decades despite advances in care. The BVA-100 blood test provides a simple, inexpensive, and objective measurement of volume status and composition. This precision enables individualization of treatment and significantly better outcomes for patients."

09:03 EDT Arthur J. Gallagher acquires Koff & Associates - Arthur J. Gallagher acquired Berkeley, California-based Kaneko & Krammer Corp, dba Koff & Associates. Terms of the transaction were not disclosed. Founded in 1984, Koff & Associates offers HR services, including job classification and analysis, compensation studies, compliance, organizational assessments, performance management programs and recruiting services, primarily throughout California. The team focuses on public sector agencies. Catherine Kaneko, Georg Krammer and their team will continue to operate from their current location under the direction of Scott Hamilton, global head of Gallagher's Human Resources & Compensation Consulting operations.

09:03 EDT Arcutis Biotherapeutics presents new data from DERMIS-1, DERMIS-2 phase 3 trials - Arcutis Biotherapeutics announced the presentation of new data from the DERMIS-1 and DERMIS-2 pivotal Phase 3 studies evaluating roflumilast cream as a potential once daily, topical treatment for chronic plaque psoriasis at the European Association of Dermatology and Venereology Spring Symposium. Roflumilast cream is a once daily topical formulation of roflumilast, a highly potent and selective phosphodiesterase type 4 inhibitor. Both Phase 3 trials achieved the primary efficacy endpoint of Investigator Global Assessment Success at week eight, with significantly more patients treated with roflumilast cream 0.3% reaching IGA success compared to the control group of vehicle-treated patients. IGA success is defined as clear or almost clear with at least a 2-grade improvement from baseline. Roflumilast also demonstrated statistically significant improvements over vehicle in key secondary endpoints, including the treatment of psoriasis presenting in intertriginous areas, as measured by intertriginous-IGA success. When plaque psoriasis presents in intertriginous areas, it can be particularly challenging to treat, with physicians often needing to prescribe a regimen of multiple medications for a single patient. In the Phase 3 trials, roflumilast was highly effective for intertriginous plaques, with significantly more roflumilast-treated patients reaching I-IGA success at week eight than vehicle-treated patients, with the vast majority of these patients achieving I-IGA=0. Other key Phase 3 findings include: Roflumilast was statistically superior to vehicle for improvement of psoriasis at all timepoints as measured by the Psoriasis Area Severity Index. Across both trials, approximately 40% of patients achieved a 75% reduction in PASI scores by week eight. Patients with clinically significant itch, as measured by a baseline Worst Itch-Numeric Rating Scale greater than or equal to 4, achieved a 4-point reduction in WI-NRS at week eight. Itch improvement was notable by two weeks, the earliest timepoint measured, with consistent improvements achieved through week eight. Roflumilast safety and tolerability were similar to vehicle, including pooled rates of treatment-related treatment-emergent adverse events, any AE leading to discontinuation and application site pain. There were no treatment-related serious AEs, and local tolerability was highly favorable for roflumilast as reported by patient and investigator assessment of irritation, burning, and stinging.

09:01 EDT Esports Technologies accepting wagers on international betting platform - Esports Technologies is accepting wagers on its international consumer platform, Gogawi.com, for the most popular esports titles, including Counter-Strike, League of Legends, Dota 2, StarCraft 2, Rainbow Six, Warcraft 3, King of Glory, FIFA and others. An upgrade to the platform is its use of the payment services solutions Apcopay, Astropay, and CoinDirect. The platform also allows for more traditional sports betting on the NFL, NBA, Soccer, and more than 40 other sports. The platform also recently added casino and table games to its betting roster thanks to its recently announced partnership with Spinomenal. Gogawi.com recently launched in Thailand.

09:00 EDT RenovaCare receives full IDE approval for safety, feasability trial - RenovaCare announced that its Investigational Device Exemption application has been granted full approval by the U.S. Food and Drug Administration. This approval enables RenovaCare to conduct a clinical trial to evaluate the safety and feasibility of its SkinGun and CellMist System for the treatment of burn wounds using skin cells obtained directly from the burn patient. The clinical trial protocol is an open-label, single-arm clinical study that will enroll 14 adult burn subjects with partial-thickness second degree thermal burn wounds. The Company expects to conduct the clinical study at four U.S. burn centers over twelve months.

08:56 EDT Hollister partners with D'Amelio sisters for Social Tourist fashion brand - Hollister is building upon its relationship with leading social media personalities Charli and Dixie D'Amelio to launch Social Tourist, a new trend-forward apparel brand within the Abercrombie & Fitch Co. portfolio. For its initial May 20 launch, Social Tourist will be available exclusively in Hollister stores and online. Social Tourist will have four distinct apparel lines: gender inclusive items, trend pieces such as dresses and skirts, everyday essentials featuring premium basics, and swim. Each collection will include limited-edition items, with new product dropping approximately every month.

08:54 EDT BellRing Brands appoints Chonda Nwamu to board of directors - BellRing Brands (BRBR) announced that Chonda Nwamu has been appointed to its board of directors, effective May 5. With the addition of Nwamu, the board now consists of six members. Nwamu currently serves as the Senior Vice President, General Counsel and Secretary for Ameren Corporation (AEE). Ms. Nwamu currently serves on the board of directors of the Boys and Girls Club of Greater St. Louis.

08:53 EDT Albireo Pharma sees cash runway into 2023 - The Company had cash and cash equivalents at March 31, 2021, of $217.1 million, which compares to $251.3 million at December 31, 2020. The Company has sufficient capital resources to fund the planned launch and development programs. Cash runway into 2023 and plans to monetize a Priority Review Voucher, if received upon approval. The 2021 operating cash burn is anticipated to be in the range of $130-$135 million. 2021 revenue from Bylvay is anticipated to be in the low single digit U.S. $ millions.

08:51 EDT ViacomCBS CEO says 'thrilled with where we are' - Says there is "clearly momentum" in streaming figures. Seeing "robust growth" in global streaming revenue. Says "unique strategy" is working. Says poised to dramatically expand movie library. Comments taken from Q1 earnings conference call.

08:47 EDT WisdomTree launches WisdomTree Alternative Income Fund - WisdomTree announced the launch of the WisdomTree Alternative Income Fund, or HYIN, on the CBOE with an expense ratio of 3.20%. HYIN seeks to track the price and yield performance, before fees and expenses, of the Gapstow Liquid Alternative Credit Index, or GLACI. Gapstow Capital Partners has created the GLACI, which is an equal weighted index that tracks the performance of debt and debt-based securities of approximately 35 "Publicly Traded Alternative Credit Vehicles" that consist of Business Development Companies, Real Estate Investment Trusts, and Closed-End Funds.

08:45 EDT General Electric acquires molecular imaging agent Zionexa, terms undisclosed - GE Healthcare announced the acquisition of Zionexa, "a leading innovator of in-vivo oncology and neurology biomarkers that help enable more personalized healthcare." The company aims to develop and bring to market Zionexa's pipeline biomarkers, as well as the recently FDA-approved PET imaging agent, Cerianna, which is used as an adjunct to biopsy for the detection of estrogen receptor positive lesions to help inform treatment selection for patients with recurrent or metastatic breast cancer. It is estimated that 168,000 people have metastatic breast cancer ("Stage 4") in the U.S.1, with a five-year survival rate of 28 percent2. Cerianna has been commercially available in the U.S. since December 2020 and today is accessible to approximately 25 percent of the relevant patient population. By leveraging its Molecular Imaging Supply Chain, R&D, Medical Affairs, Market Access, Regulatory, Quality and Commercial expertise, GE Healthcare's Pharmaceutical Diagnostics business - the global leader in pharmaceutical imaging agents - aims to scale Cerianna to be accessible to a minimum of 75 percent of patients by 2023. Kevin O'Neill, President and CEO of GE Healthcare Pharmaceutical Diagnostics, said: "Like GE Healthcare, Zionexa's products are aimed at enabling more precise diagnosis, improved treatment decision-making and ultimately better clinical outcomes for patients. This acquisition further demonstrates our commitment to enabling precision health and providing innovations that support oncologists, nuclear medicine specialists and other physicians throughout a cancer patient's journey, from initial screening and diagnosis to informing therapy selection and monitoring the effectiveness of treatment."

08:42 EDT AMMO, Mill City Ventures III partner on GunBroker.com customer financing - AMMO is pleased to announce that it has entered into a non-binding Letter of Intent with Mill City Ventures III, a non-bank lender and specialty finance company, whereby the two companies will work together to provide GunBroker.com customers with the option to purchase items through the GunBroker.com website using short-term consumer financing provided by Mill City.

08:40 EDT Generex's NuGenHealth contracts with FHCA to provide remote patient monitoring - Generex announces that its subsidiary NuGenHealth has signed a contract with Florida Health Care Associates, FHCA, to provide connected care solutions for patient engagement and Remote Patient Monitoring, or RPM, services. NuGenHealth, a joint venture between Generex subsidiary NuGenerex Health and Worldwide Digitech, will provide the software, data framework and back-end support for the NuGenHealth SaaS system to advance collaborative, connected care in order to improve patient health outcomes for patients under the care of FHCA. Under the terms of the agreement, NuGenHealth will provide the SaaS system and implementation, personnel training, and system oversight to optimize workflows for RPM and to collect, analyze, and report real-time patient data. NuGenHealth will also supply FHCA with Bluetooth connected blood pressure monitors, electronic scales, glucose monitors, and pulse oximeters for their eligible patient population. In collaboration with and assistance from the NuGenHealth implementation team, FHCA will implement the NuGenHealth SaaS suite on site, handle the initial onboarding of patients, train their patients on the use of the monitoring devices, and manage the day-to-day monitoring of their RPM patient population.

08:40 EDT ProPhase Labs to provide COVID testing to Dutchess County, New York - ProPhase Labs announced that it has signed a contract with Dutchess County, New York to provide reliable COVID-19 testing to its nearly 300,000 residents within 22 towns and four villages. ProPhase was awarded the contract after a highly competitive process in which it was able to demonstrate its distinguished multiplex RT-PCR testing, which offers over 99 percent accuracy and provides results within 24-hours that can be reported directly to a patient's smartphone.

08:38 EDT Aeterna Zentaris announces selection of development candidate in DC-PTH program - Aeterna Zentaris through its wholly-owned subsidiary Aeterna Zentaris GmbH announced that, in consultation with The University of Sheffield, UK, Aeterna has selected AEZS-150 as the lead candidate in the company's delayed clearance parathyroid hormone fusion polypeptides program. Aeterna will now start the formal preclinical development of AEZS-150 in preparation for a potential IND filing for conducting the first in-human clinical study of AEZS-150. AEZS-150 is being developed with the goal of providing a potential new treatment option of primary hypoparathyroidism in adults. AEZS-150 is a DC-PTH consisting of a modified growth hormone binding protein linked to PTH1-34. It is being developed with the goal of producing a product with delayed clearance of one or two weeks and the potential to be self-administered via a pharmaceutical pen. If successful, it would help patients maintain normal serum calcium and phosphate levels during chronic use. The technology is based on proprietary intellectual property exclusively licensed by Aeterna from the University.

08:36 EDT Color Star Technology to sell portion of 'Guilt' movie as NFT - Color Star Technology announced that it will sell a portion of the content of the movie "Guilt" as a NFT. Since its release, the movie "Guilt" has received a great deal of attention. The film, which is adapted from real events, has sparked lively discussion. The Company has decided to sell parts of the unreleased content of the movie as a NFT. The introduction of Color Star's NFT products is a new application of blockchain technology. The company has always believed that the blockchain technology of non-fungible token suits the entertainment industry best. This technology not only promotes the development of entertainment copyrights, but also benefits materially the copyrights owners. With this NFT application in place, Color Star will continue to launch more NFT-related products in areas such as music copyrights and TV copyrights.

08:35 EDT Fastenal reports April sales up 1.2% to $497.1M - Fastenal reported April net sales of $497.14M, up 1.2% compared to the same month of 2020. The company reported April daily sales of $22.6M, up 1.2% year-over-year. Reference Link

08:32 EDT Quanta's Medolife implements proprietary electro solution, increase efficacy - Medolife Rx, which is a majority owned subsidiary of Quanta, announced that it has successfully implemented a new technology into its polarization methodology that further increases the effect of polarization, where it increases efficacy and potency of active pharmaceutical ingredients for use in pharmaceutical and nutraceutical products. Proprietary to the company, the original polarization technology was developed by Medolife CEO Dr. Arthur Mikaelian and increases the potency of single molecules and complex compounds. The polarization process leverages quantum biology with the goal of creating a resonating effect. "Medolife leverages this polarization technology in both its nutraceutical consumer wellness products as well as in its pharmaceutical drug candidates, where the company is conducting clinical trials in the areas of the SARS-CoV-2 virus and various forms of cancer," the company said. The company's lead product is Escozine, a proprietary formulation consisting of small molecule peptides derived from Rhopalurus princeps scorpions, is amplified by the company's polarization technology. The company has recently announced milestones in its pharmaceutical programs, culminated in its first major drug product registration in the Dominican Republic, allowing for sales of Escozine throughout Latin America.

08:29 EDT Insight Enterprises CEO Ken Lamneck plans to retire - Insight Enterprises, announced that Ken Lamneck plans to retire as President and Chief Executive Officer effective December 31, 2021. Mr. Lamneck, 66, has been with the company since January 1, 2010. Mr. Lamneck will continue to serve as the President and CEO and a member of the Board until a successor has been named. He will then transition to an advisory role.

08:28 EDT Copper Hop Brewing Co. enrolls in DTE Energy's MIGreenPower program - Copper Hop Brewing announced its enrollment in DTE Energy's MIGreenPower program. MIGreenPower provides DTE Electric customers with a turnkey solution to achieving their sustainability goals by attributing their energy use to Michigan wind and solar parks. Copper Hop will be attributing 100% of its energy use to renewable energy and is the first brewery to enroll in the program.

08:27 EDT Metromile to accept insurance premiums, pay claims in bitcoin - Metromile (MILE) announced it will soon allow policyholders the option to pay for insurance and receive payment for eligible and approved insured claims in bitcoin (BTC) or dollars. Metromile will purchase $10M of bitcoin in Q2 2021 to adopt cryptocurrency as an additional choice for insurance premiums and payment of claims. Metromile believes allowing cryptocurrency payments will support its commitment to fairer insurance and promote financial resilience for policyholders as cryptocurrency becomes mainstream and a more significant portion of consumers' assets.

08:26 EDT Fulgent Genetics welcomes Dr. Lawrence Weiss as Chief Medical Officer - Fulgent Genetics announced the appointment of Lawrence Weiss, M.D. as Chief Medical Officer, reporting to the Company's Chief Executive Officer, Ming Hsieh. Dr. Weiss will be responsible for expanding Fulgent's reach in molecular diagnostics and driving the advancement of the Company's portfolio of oncologic testing solutions.

08:24 EDT Nemaura Medical progress on listing sugarBEAT for reimbursement in Germany - Nemaura Medical announced progress with the German regulatory authority, or GBA, to achieve reimbursement for its sugarBEAT device. After initial review, the GBA has determined that sugarBEAT does not require GBA review and will go directly to the National Association of Statutory Health Insurance Funds for a listing on the durable medical catalog. The company is now completing the application for this listing, which is expected to be faster than where a GBA review is required.

08:23 EDT Fusion Pharmaceuticals announces clinical trial collaboration with Merck - Fusion Pharmaceuticals (FUSN) announced that it has entered into a clinical trial collaboration with a subsidiary of Merck (MRK) to evaluate Fusion's lead candidate, (FPI-1434), in combination with Merck's anti-PD-1 therapy, KEYTRUDA, in patients with solid tumors expressing insulin-like growth factor 1 receptor. The planned Phase 1/2 combination trial will evaluate safety, tolerability and pharmacokinetics of FPI-1434 in combination with pembrolizumab and is expected to initiate approximately six to nine months after achieving the recommended Phase 2 dose in the ongoing Phase 1 study of FPI-1434 monotherapy. Under the terms of the agreement, Fusion will sponsor the study and Merck will supply KEYTRUDA.

08:21 EDT Alithya Group awarded C$10M multi-year contract - Alithya Group announced that it has been awarded a multi-year contract with a C$10M dollars initial value for plant level Operational Technology cyber security consulting services in the North American manufacturing/utilities sector. The contract was awarded to support strategic cyber security initiatives and ensure compliance to the latest industry regulated cyber security standards.

08:20 EDT Canacol Energy says gas sales averaged 166 MMscfpd for April - Canacol Energy is pleased to provide the following information concerning its April 2021 natural gas sales and drilling program. Realized contractual natural gas sales were 166 million standard cubic feet per day for April 2021. Nelson 9 development well and Agua Vivas 1 exploration well: The Nelson 9 development well encountered 52 feet true vertical depth of gas pay within the Porquero sandstone target, and will be tied in and on production by early May 2021. The Aguas Vivas 1 exploration well is expected to spud prior to Mid May 2021.

08:19 EDT Ocugen presents new preclinical data on OCU200 at ARVO annual meeting - Ocugen announced the presentation of a pre-clinical study to evaluate efficacy of OCU200 in in-vitro and in-vivo models for ocular neovascular diseases. The data will be featured in a virtual poster presentation entitled "OCU200: A potential therapeutic for DME, DR, and wet-AMD" at the Association for Research in Vision and Ophthalmology, or ARVO, 2021 Annual Meeting, taking place May 1-7. OCU200 is a biologic product candidate in preclinical development for treating severely sight-threatening diseases like Diabetic Macular Edema, Diabetic Retinopathy, and Wet Age-Related Macular Degeneration. The purpose of this study was to evaluate efficacy of OCU200 in in-vitro and in-vivo models for ocular neovascular diseases. Angiogenesis and neovascularization are hallmarks for DME, DR, and wet-AMD. Most approved therapeutics target vascular endothelial growth factor, a pro-angiogenic factor with neurotrophic and neuroprotective effects. However, approximately 50% of Patients do not respond to anti-VEGF/Corticosteroids therapies. OCU200 inhibited cell proliferation, cell invasion and tube formation by endothelial cells. In an oxygen induced retinopathy mice model, OCU200 significantly reduced avascular areas at low dose and high dose, and significantly reduced neovascular tufts at low dose compared to vehicle-treated eyes. Aflibercept reduced NVs by 77%. OCU200 showed comparable activity to aflibercept. These findings suggest that OCU200 represents a potential therapeutic for the treatment of DME, DR, and wet-AMD.

08:18 EDT Maxeon Solar, Clean Capital Energy announce partnership - Maxeon Solar announced that it has been selected by Clean Capital Energy Group, one of Austria's largest and most experienced solar energy service company, as their primary premium solar panel technology provider to build a growing base of residential and commercial solar customers in Austria. This partnership comes after more than 2 years of collaboration with CCE as an official installation partner.

08:17 EDT Silicom awarded design win for Smart 5G acceleration card - Silicom announced that one of the world's largest mobile infrastructure equipment providers has awarded it a design win for a customized version of one of its Smart 5G acceleration cards. The customer will immediately begin integrating Silicom's current standard card into its Distributed Unit solution for PoCs and initial deployments. In parallel, Silicom will develop another version of the card to be used by the customer for mass deployments.

08:17 EDT Thryv Holdings announces global partnership with MasterCard - Thryv Holdings (THRY) announced today a global partnership with Mastercard (MA). Initial engagements include Thryv joining the Mastercard Digital Doors program and co-sponsoring a small business digital education series to help owners better manage and grow their business. Mastercard's partnership with Thryv is part of the company's pledge to bring 1B people and 50M micro and small businesses into the digital economy by 2025. Initial activities from the collaboration will see Thryv join the Mastercard Digital Doors program. Thryv will provide access to its platform on Digital Doors "to help small businesses expand their online presence and better manage operations," the company said.

08:15 EDT Marathon Gold provides Valentine Gold Project update - Marathon Gold Corporation is pleased to provide an update on its plans regarding the continued exploration and development of the Valentine Gold Project, central Newfoundland. Marathon recently published a Feasibility Study for the Project demonstrating robust economics for a conventional open pit mining and milling operation with low initial capital cost and high rate of return. An Environmental Assessment for the Project is ongoing with federal and provincial regulators, and is expected to be completed later this year. Marathon's 2021 exploration program continues to deliver strong results, with a recent mineral resource estimate for the new Berry Deposit demonstrating mine life extension potential for the Project. On this basis, Marathon announces the following: Expanding Exploration and Resource Drilling. An additional 50,000 metres of drilling will be targeted at the Berry Deposit, to be completed over the next 15 months. Together with drilling completed in 2020, and the 30,000 metres of drilling already budgeted for 2021, this will bring the total drilling inventory at Berry to approximately 120,000 metres by mid-2022, sufficient to establish Berry's resource potential over its full 1.5 kilometre long extent. Marathon will also continue to aggressively pursue additional opportunities for resource growth elsewhere within the Valentine Lake property. Testing the Mineral Resource. Marathon will commence a Reverse Circulation drill program of approximately 8,000 metres on the Leprechaun and Marathon Deposits, designed to test resource reconciliation and grade distribution broadly over both deposits. The program will comprise 6 x 12 metre drill spacings to a depth of up to 50 metres, and will commence later this month. Results will be available by the third quarter of this year. Environmental Assessment Proceeding with No Change to Project Scope. Consistent with the Company's previously stated plans, Marathon will seek to complete the current EA process expeditiously, with no changes to the project scope or the mine plan described in the FS and the Project's Environmental Impact Statement. This is based on two open pits at Marathon and Leprechaun and a central 2.5 to 4 million tonne per annum mill. Following release from the EA, and upon Project approval, Marathon will commence applications for the site-specific sectoral permits required for the construction of this mine design. De-risking and Re-ordering Mine Construction. The FS contemplates project construction commencing immediately upon receipt of sufficient permits, with first gold pour in October 2023. With a view to optimising the conditions for a successful on-budget and on-schedule Project build, Marathon is assessing an execution strategy of first commencing construction on the Project's essential infrastructure elements, such as the NL Hydro powerline, site communication systems, camp facilities, and upgrades to access roads and bridges. With this well in hand, site-based construction would commence later in 2022. A development budget and schedule for this de-risked execution strategy, including a revised date of first gold production, will be prepared by the Company in the fourth quarter of this year in support of a construction decision by the Company's Board of Directors. Detailed engineering in support of this work has already commenced.

08:14 EDT FDA approves Orgenesis IDE for pilot clinical trial of Tissue Genesis Icellator2 - Orgenesis announces it has been granted Investigational Device Exemption approval by the Food and Drug Administration to conduct a first-in-human feasibility study of the Tissue Genesis Icellator2 to treat Acute Respiratory Distress Syndrome resulting from COVID-19 infection. The Tissue Genesis Icellator2 is a point-of-care cell isolation device that rapidly recovers high yields of stromal and vascular cells from adipose tissue to be used therapeutically. The SVF derived from the Icellator2 contains a population of mesenchymal stem cells, vascular endothelial cells, and immune cells which migrate to the patient's lungs and other peripheral sites of inflammation. Published nonclinical and clinical evidence indicate that SVF from the Icellator2 may potentially: stabilize microcirculation to improve oxygenation; maintain T and B lymphocytes to support antibody production; and induce an anti-inflammatory effect. Orgenesis believes the multiple mechanisms of action of the SVF derived from the Icellator2 are important to treat ARDS and other inflammatory disorders. The FDA IDE approval covers 21 patients at one clinical site in the United States. This is the first trial approved by the FDA for intravenous administration of the SVF produced by the Icellator2.

08:12 EDT Biofrontera reports April revenue EUR 6.6M vs. EUR 6M last year - The Company's preliminary, unaudited revenue from product sales in April 2021 amounted to approximately EUR 2,491 thousand, compared to EUR 492 thousand in April 2020, an increase of 406%. The company said, "The sales increase compared to the previous year already perceived since mid-March 2021, especially in our most important sales market, the USA, continued strongly in April 2021. This indicates a significant recovery of the COVID-19 situation in the USA as well as in Germany - presumably also due to the high vaccination rates."

08:11 EDT Antares Pharma appoints Joseph Renda as SVP, commercial - Antares Pharma announced the appointment of Joseph Renda as Senior Vice President of Commercial. Mr. Renda succeeds Patrick Shea who resigned to pursue other interests. Prior to joining Antares, Mr. Renda was Vice President, U.S. Sales Autoimmune and Rare Disease at Mallinckrodt Pharmaceuticals.

08:08 EDT Amicus appoints Sebastien Martel as SVP, strategy and business development - Amicus Therapeutics (FOLD) announced the appointment of Sebastien Martel as Senior Vice President of Strategy and Business Development. Mr. Martel will lead the Company's corporate strategy and business and corporate development endeavors. He will be a member of the Amicus senior leadership team. Mr. Martel brings 25 years of diversified pharmaceutical and biotechnology expertise to Amicus, with extensive experience in rare disease, most recently as Senior Vice President, Global Head of Rare Diseases at Sanofi (SNY).

08:06 EDT Kratos Defense awarded $46M to support space domain awareness efforts - Kratos Defense & Security Solutions announced that it has received multiple awards totaling more than $46M to support Space Domain Awareness efforts.

08:04 EDT Fulcrum Therapeutics appoints Christopher Morabito as Chief Medical Officer - Fulcrum Therapeutics announced Christopher Morabito, M.D. has been appointed Chief Medical Officer, effective May 10. Dr. Morabito will oversee the development of Fulcrum's lead programs in facioscapulohumeral dystrophy and select hemoglobinopathies, including sickle cell disease. Most recently, Dr. Morabito served as Chief Medical Officer at Cardurion Pharmaceuticals.

07:58 EDT Corvus Gold receives $20M loan from AngloGold Ashanti North America - Corvus Gold (KOR) announces it has entered into a $20M loan agreement with AngloGold Ashanti North America Inc. (AU) to fund the ongoing permitting and pre-development work at the Company's North Bullfrog project as well as ongoing exploration at its Mother Lode and Lynnda Strip projects. Highlights of the agreement for the $20M unsecured loan include: A fixed interest rate of 1.10725% with interest beginning 180 days after Loan signing; Repayment of Loan will be the lesser of 12 months after Loan origination date, or after all North Bullfrog project mine construction permits are obtained by Corvus; A minimum of 70% of the Loan amount to be spent on project work; AngloGold is granted an exclusivity period of 90 days where Corvus will abstain from all discussions or actions related to material transactions involving Company assets or change in share structure. The Loan constitutes a "related party transaction" under Multilateral Instrument 61-101 -- Protection of Minority Security Holders in Special Transactions as AngloGold is a related party of Corvus given its greater than 10% beneficial shareholding. Pursuant to Section 5.7(1)(f) of MI 61-101, the Company is exempt from obtaining minority approval of the Company's shareholders in respect of the Loan because it was determined that the Loan is on reasonable commercial terms that are not less advantageous to the Company than if the Loan was obtained from a person dealing at arm's length with the Company and because the Loan is not convertible into, or repayable in, equity or voting securities of the Company or a subsidiary of the Company or otherwise participating in nature. The Company will file a material change report in respect of the Loan. However, the material change report will be filed less than 21 days prior to the closing of the Loan, which is consistent with market practice and which the Company deems reasonable in the circumstances. This transaction remains subject to TSX acceptance.

07:56 EDT CVS Health to administer no-cost COVID-19 vaccines at 19 locations in NH - In an ongoing effort to expand access to COVID-19 vaccines and help the country move forward from the pandemic, CVS Health announced that it will begin vaccinating eligible populations on Sunday, May 9 at 19 select CVS Pharmacy locations throughout New Hampshire. Participating CVS Pharmacy locations are in the following New Hampshire communities: Bedford, Concord, Greenland, Hampton, Hanover, Hooksett, Hudson, Keene, Laconia, Londonderry, Manchester, Merrimack, Nashua, Portsmouth, Somersworth, and Stratham.

07:53 EDT Luokung Technology announces favorable ruling granting preliminary injunction - Luokung Technology announced that Luokung's previously announced motion for a preliminary injunction was granted by the United States District Court for the District of Columbia. In its ruling, the Court explained that it was preliminarily enjoining "the prohibitions against Luokung in full." As a result of the ruling, the Department of Defense and other government defendants are enjoined from implementing or enforcing the designation of Luokung as a Community Chinese military company, and the resulting restrictions pursuant to Executive Order 13959.

07:52 EDT Mogo in partnership with Tom Lee's Fundstrat for crypto research - Mogo announced a new partnership to provide MogoMembers with exclusive access to crypto and other equity research from FSInsight, a division of Fundstrat Global Advisors ("Fundstrat"). Fundstrat/FSI was founded by Thomas J. Lee, CFA-a top-ranked Wall Street analyst with 30 years of research experience, the former Chief Equity Strategist at global investment bank JPMorgan, and a contributing editor with CNBC-and veteran Wall Street sales executive John Bai. FSI provides individuals with the same quality of research that banks and hedge funds receive to make their investment decisions. Under the agreement, Mogo will be the exclusive distributor bringing FSI's research to Canada's retail investor market. Mogo will make FSI research available to MogoMembers. The focus will be on crypto research and related research products and services produced by FSI, including free weekly and monthly crypto briefings, access to exclusive interviews, and preferred access to monthly and annual subscription-based crypto research available through FSI. MogoMembers will also have access to exclusive quarterly webinars with Tom Lee.

07:50 EDT EQT Corporation to acquire membership interests in Alta subsidiaries for $2.93B - EQT Corporation announced that it has entered into a purchase agreement with Alta Resources Development, pursuant to which EQT will acquire all of the membership interests in Alta's upstream and midstream subsidiaries for approximately $2.93B, subject to customary closing adjustments. The transaction is expected to close in Q3, with an effective date of January 1. The total purchase price for the transaction is $2.93B, consisting of $1B in cash and approximately $1.93B in EQT common stock issued directly to Alta's shareholders. The company expects to fund the $1B of cash consideration with cash on hand, drawings under its revolving credit facility and/or through one or more debt capital markets transactions, subject to market conditions and other factors. The stock consideration consists of approximately 105M shares of EQT common stock representing $1.93B, based on the 30-day volume-weighted average price as of May 5. The transaction was unanimously approved by the board of directors. EQT shares issued as part of the transaction will be distributed directly to Alta shareholders, which represent a diverse set of financial institutions and individuals. No Alta shareholder will receive more than 5% of EQT's pro forma outstanding shares of common stock in connection with the transaction. The transaction is expected to close in Q3, subject to satisfaction of customary closing conditions, including the approval by EQT's shareholders of the issuance of the common stock consideration. All post effective date purchase price adjustments will be netted against the stock consideration and are expected to result in a reduction of approximately 11M shares issued at closing.

07:48 EDT Intellia Therapeutics announces anticipated milestones for 2021 - The Company has set forth the following for pipeline progression: ATTR: Report initial clinical data from Phase 1 study of NTLA-2001 in mid-2021; AML: Submit an IND or IND-equivalent for NTLA-5001 in mid-2021; HAE: Submit an IND or IND-equivalent for NTLA-2002 in 2H 2021; Nominate at least one new development candidate in 2021.

07:43 EDT Fulcrum Therapeutics expects cash to fund requirements into 4Q22 - As of March 31, 2021, cash, cash equivalents, and marketable securities were $143.9 million, as compared to $112.9 million as of December 31, 2020. Based on current plans, the company expects that its existing cash, cash equivalents, and marketable securities will be sufficient to enable it to fund its operating expenses and capital expenditure requirements into the fourth quarter of 2022.

07:41 EDT Domtar sees paper demand rebounding through the year - The company stated, "Paper demand will remain dependent upon recovery from COVID-19, but demand is expected to continue to rebound through the year as people return to schools and offices. Near-term pulp markets should remain balanced due to steady demand growth and limited new supply. Recently announced price increases in both pulp and paper will positively impact our results. The second quarter will be affected by seasonally higher maintenance costs in our Pulp and Paper business as we move into the planned outages at some of our major facilities."

07:37 EDT Chimerix announces expected 2021 milestones - FDA PDUFA action date set for July 7, 2021 for BCV smallpox NDA. Potential procurement agreement for BCV around the time of FDA decision on smallpox NDA, if favorable. Completion of Phase 2 trial of DSTAT in COVID-19 related ALI. Completion of BCV drug product manufacturing to support potential shipments to the SNS of up to $100 million. Blinded independent central review of 50-subject registration cohort of ONC201 in recurrent H3 K27M-mutant glioma.

07:33 EDT Athenex expects 2021 product sales in line with 2020 levels - In terms of product sales guidance, the Company is limiting financial guidance to only the existing product portfolio, which excludes any proprietary products, until meaningful sales data from the proprietary product, Klisyri, become available. In 2020, the Company recorded a significant amount of revenues from international customers as a result of the global pandemic. However, the Company does not see these revenues as recurring in nature. The Company continues to expand its product portfolio. The Company is affirming the guidance it provided on March 1, 2021, as it currently expects its product sales in 2021, excluding any royalties from Klisyri, to be in line with 2020 levels.

07:31 EDT Kymera Therapeutics provides updated milestones for degrader programs - Expected milestones for IRAK4 degrader program include: presentation of KT-474 preclinical data at the American Association of Immunologists' Virtual IMMUNOLOGY2021 annual meeting; initiation of enrollment in multiple ascending dose portion of Phase 1 trial of KT-474 pending FDA clearance, including healthy volunteers and a subsequent cohort of patients with atopic dermatitis or hidradenitis suppurativa; establish Phase 1 proof-of-biology in healthy volunteers in Q4. Expected milestones for IRAKIMiD degrader program include; submission of KT-413 IND application, and if cleared, initiation of Phase 1 clinical trial in relapsed/refractory B cell lymphomas, including MYD88-mutant DLBCL in second half of 2021; presentation of additional KT-413 preclinical data and potential indication expansion strategies in second half of 2021; and establish Phase 1 proof-of-biology and initial clinical proof-of-concept in patients in 2022. Expected milestones for the STAT3 degrader program include: presentation of additional preclinical data in liquid and solid tumors in second half of 2021; submission of KT-333 IND application, and if cleared, initiation of Phase 1 clinical trial in relapsed/refractory liquid and solid tumors in fourth quarter; and establish Phase 1 proof-of-biology and initial clinical proof-of-concept in patients in 2022.

07:27 EDT Autolus Therapeutics announces key upcoming milestones - Key Upcoming Clinical Milestones: AUTO1 updates in 2021 on ALLCAR19 in patients with r/r B-NHL and longer term follow up of the fully enrolled r/r aALL cohort. AUTO1 - Currently enrolling a potentially pivotal Phase 1b/2 clinical trial in r/r adult ALL patients with data expected in 2022. Updates on Phase 1 programs AUTO1/22 in pediatric ALL, as well as AUTO4 in TRBC1+ Peripheral TCL, in 2021. Phase 1 trials are expected to be initiated in 2021 with AUTO1 in Primary CNS Lymphoma, AUTO5 in TRBC2+ Peripheral TCL, AUTO6NG in Neuroblastoma, and AUTO8 in Multiple Myeloma. First exploratory allogeneic program expected to enter the clinic in 2021.

07:22 EDT Intercept lowers FY21 Ocaliva revenue view to $325M-$340M from $325M-$355M - The company said, "As a result of the latest dialogue with the FDA, which we expect to result in a label update restricting the use of Ocaliva in patients with decompensated cirrhosis and in a subset of patients with compensated cirrhosis, we are narrowing our Ocaliva net sales guidance range. We now expect full year 2021 worldwide Ocaliva net sales to be between $325M-$340M. Once the label is finalized and as we monitor post-label update market dynamics, we will plan to refine this range throughout the year as necessary. We are reiterating our full year 2021 non-GAAP adjusted operating expenses to be between $380M-$410M."

07:18 EDT Aaon: Backlog at beginning of May up 'considerably' from end of Q1 - The company said: "We are confident demand is improving. Our backlog at the beginning of May was up considerably from both the end 2020 and the end of the first quarter. Replacement demand is already improving as the economy recovers, and while the new construction market is still facing some challenges, we are beginning to see signs of stabilization. Inflation remains a challenge, but we are confident we will be able to maintain our margin through disciplined price management. In conclusion, as we look to the rest of the year, we continue to anticipate revenue and earnings will progressively improve throughout 2021."

07:17 EDT ProQR Therapeutics provides update on sepofarsen - Upcoming anticipated sepofarsen events include the following. Report top-line results from the pivotal Phase 2/3 Illuminate trial in H1 2022. The Illuminate trial completed enrollment in January following randomization of 36 patients aged 8 years or older to receive either sepofarsen at the target registration dose, a low dose, or sham treatment. The primary endpoint for Illuminate is mean change from baseline in best-corrected visual acuity at Month 12. Report updated data from the next interim analysis of the Phase 1/2 InSight extension study in H2 2021.

07:15 EDT SpringsWorks Therapeutics enters license agreement with KU Leuven, VIB - SpringWorks Therapeutics announced that it has entered into an exclusive worldwide license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for the in-license of a portfolio of novel small molecule inhibitors of the TEA Domain family of transcription factors, designed for the potential treatment of biomarker-defined solid tumors driven by aberrant Hippo pathway signaling. Under the terms of the agreement, SpringWorks will pay KU Leuven and VIB an upfront payment of $11M. KU Leuven and VIB are also eligible to receive up to $285M in development, regulatory and commercial milestones from SpringWorks and tiered single-digit percentage royalties based on any future net sales.

07:14 EDT Nintendo sold 28.8M Switch consoles in FY ended March - Nintendo said that the results for this fiscal year showed strong software sales for Nintendo Switch, which contributed greatly to the growth of hardware sales. In particular, sales continued to grow for titles released in previous fiscal years, with units of Animal Crossing: New Horizons at 20.85 million, Mario Kart 8 Deluxe at 10.62 million, and Ring Fit Adventure at 7.38 million. As a result, hardware sales reached 28.83 million units, an increase of 37.1% year-on-year, and software sales reached 230.88 million units, an increase of 36.8% year-on-year.

07:11 EDT Trevena expects cash to fund requirements through 4Q22 - Cash and cash equivalents were $97.7 million as of March 31, 2021, which the Company believes will be sufficient to fund the Company's operating expenses and capital expenditure requirements through the fourth quarter of 2022.

07:05 EDT Norwegian Cruise Line reports $1.3B in advance ticket sales as of Mar. 31 - The company said, "Bookings have been strong for future periods resulting in an elongated booking window as guests book further into the future, despite reduced sales and marketing investments and a travel agency industry that has not been at full strength for months. During the first quarter 2021, overall bookings, net of cancellations, were more than double the volumes during the prior quarter. 2022 booking and pricing trends are very positive driven by strong pent up demand. The Company is experiencing robust future demand across all brands with the overall cumulative booked position for the first half of 2022 meaningfully ahead of 2019's record levels with pricing higher when excluding the dilutive impact of future cruise credits. As of March 31, 2021, the Company had $1.3 billion of advance ticket sales, including the long-term portion of advance ticket sales, which includes approximately $0.85 billion of FCCs."

07:01 EDT Denbury still expects 2021 production 47,500-51,500 BOE/d - Development CapEx for 2021 are still expected at $250M-$270M.

06:55 EDT ChemoCentryx trading halted, news pending

06:50 EDT Tapestry sees FY revenue up at mid-teens rate vs. prior year - Due to the dynamic nature of the Covid-19 crisis and lack of visibility, the company is not providing detailed guidance for fiscal 2021. However, given Tapestry's better-than-anticipated results year-to-date, and assuming a continued recovery emerging from the pandemic, the company now expects revenue for the fiscal year to increase at a mid-teens rate compared to prior year on both a 52 and 53-week basis. This outlook now includes the expectation for fiscal year 2021 operating income and earnings per diluted to share to increase versus fiscal year 2019 on a 52 and 53-week basis.

06:49 EDT Tapestry CEO: Results significantly outpaced expectations - Joanne Crevoiserat, Chief Executive Officer of Tapestry, Inc., said, "Our third quarter results significantly outpaced expectations, underscoring the power of the Acceleration Program and enthusiasm for our brands. Through a sharpened focus on the consumer, we fueled new customer acquisition at Coach, Kate Spade, and Stuart Weitzman and delivered robust sales growth led by Digital and China. Importantly, for the third consecutive quarter, we achieved operating income gains - compared to both FY20 and FY19 - supported by a continued reduction in promotional activity, higher AUR, and disciplined expense management... Building on this momentum, we are increasingly optimistic about our ability to generate sustainable top and bottom-line growth. Looking forward, while the environment remains volatile, we see encouraging signs of recovery as vaccination efforts progress, resulting in increased consumer confidence, strong demand for our categories, and improving in-store traffic trends. In this context, we remain focused on driving brand relevance and customer engagement through product innovation and compelling marketing, supported by data-driven insights and a digital-first mindset."

06:43 EDT Becton Dickinson announces intention to spin off Diabetes Care business - Becton Dickinson announced its board of directors has unanimously authorized management to proceed with a plan to spin off the company's Diabetes Care business as an independent, publicly traded company, or NewCo. BD believes the spinoff of the Diabetes Care business will create long-term value for BD shareholders and create a platform to continue to enhance the tools provided to people with diabetes. The transaction is expected to create two, independent companies. BD management expects that, as a separate independent entity, NewCo will be better positioned to pursue its strategic priorities and attract new investors. BD expects the spinoff to be accomplished through a distribution of stock in NewCo to BD shareholders. The spinoff is expected to be tax-free for U.S. federal income tax purposes, except to the extent of any cash received in lieu of fractional shares. BD does not expect the spinoff to impact its current dividend. The transaction is also expected to be completed in the first half of calendar year 2022, subject to the satisfaction of customary conditions, including final approval from the BD board of directors, regulatory approvals and the effectiveness of a Form 10 registration statement that will be filed with the SEC. Devdatt Kurdikar, currently worldwide president of BD Diabetes Care, will be CEO of NewCo. Kurdikar joined BD in February.

06:36 EDT Targa Resources sees 2021 adjusted EBITDA $1.8B-$1.9B

06:27 EDT Volkswagen sees 2021 operating return on sales 5.5%-7% - The company said, "Based on the positive business performance in the first quarter of 2021, the Volkswagen Group is raising its forecast for operating profit, net cash flow and net liquidity. he Group anticipates that - assuming successful containment of the Covid-19 pandemic - deliveries to customers in 2021 will be significantly up on the previous year amid continued challenging market conditions. Challenges will arise particularly from the economic situation, the increasing intensity of competition, volatile commodity and foreign exchange markets, securing supply chains and more stringent emissions-related requirements. Sales revenue of the Volkswagen Group in 2021 are expected to be significantly higher than the prior-year figure. In terms of the operating profit, the Group anticipates an operating return on sales of between 5.5 and 7.0 percent in 2021. In the Automotive Division, net cash flow is expected to rise strongly over the prior year with lower cash outflows from diesel and significantly higher effects from mergers and acquisitions, which will lead to a significant rise in net liquidity. The plans are based on the Volkswagen Group's current structures. The intended acquisition of all outstanding shares in Navistar International Corporation and associated effects on the results of operations, financial position and net assets are not included in the Volkswagen Group forecast."

06:18 EDT AB InBev sees FY21 normalized EBITDA up 8%-12%, revenue ahead of EBITDA - The company said: "We expect our FY21 normalized EBITDA to grow between 8-12% and our revenue to grow ahead of EBITDA from a healthy combination of volume and price. The outlook for FY21 reflects our current assessment of the scale and magnitude of the COVID-19 pandemic, which is subject to change as we continue to monitor ongoing developments. We expect the normalized ETR in FY21 to be in the range of 28% to 30%, excluding any gains and losses relating to the hedging of our share-based payment programs. The increase versus 2020 is due to factors including the phasing out of temporary COVID-19 measures and changes to tax attributes in some key markets."

06:10 EDT EssilorLuxottica expectes to deliver 2021 performance comparable to 2019 - The company said, "EssilorLuxottica confirms its confidence in its ability to outperform the eyecare and eyewear industry in 2021, thanks to continued innovation in products and processes and ongoing evolution of the consumer journey.The Company now has the ambition to deliver a performance that is at least comparable to 2019 in both revenue and adjusted operating profit margin, at constant exchange rate. This takes into account the positive momentum in several areas of the business and the gradual normalization of the business environment due to vaccination campaigns, while also weighing the remaining uncertainties around COVID-19."

06:03 EDT AB InBev names Michel Doukeris to succeed Carlos Brito as CEO - Anheuser-Busch InBev announced that its Board of Directors has unanimously elected Michel Doukeris, President of AB InBev's North America Zone, to succeed Carlos Brito as CEO effective July 1, 2021. Brito will step down after 15 years as CEO and 32 years at the company. "We are grateful to Brito for his tremendous service and leadership," said AB InBev Board Chairman Martin Barrington. "Among his many accomplishments, Brito was the architect who led and built AB InBev into the world's leading beer company and a leading global consumer packaged goods company by masterfully integrating the many businesses that comprise AB InBev today. He has always been a role model of the company's successful ownership culture. The Board thanks Brito for his dedicated service, passion, caring and commitment to making our company dream big and delivering." Barrington added: "After conducting a rigorous and robust selection process, the Board is delighted that our next CEO comes from our deep bench of leadership talent. Michel is the right leader to take the company into its next phase of organic growth and success. He has a proven track record in innovation, multi-category brand building in beer and adjacencies, consumer insight, and expanding premium brands in both emerging and developed markets. The Board is excited to continue to work closely with Michel as we grow the company."

05:44 EDT ObsEva CCO Wim Souverijns to leave, Clive Bertram to succeed - ObsEva announced the appointment of Clive Bertram as chief commercial officer, or CCO, and member of ObsEva's executive committee, effective May 10. Wim Souverijns has served as chief commercial officer of ObsEva since November 2018 and will leave the company on June 30 to pursue a new opportunity. He will work to ensure a transition with Bertram. Bertram joins ObsEva with nearly 30 years of experience in commercialization, strategic, corporate and business development in the pharmaceutical industry. Most recently, he served as chief commercial officer at Petra Pharma and Sangart.

05:26 EDT Sanofi enters three-year research collaboration with Stanford University - Sanofi has entered into a three-year research collaboration with Stanford University School of Medicine. Together, the two organizations and their scientists will work to advance the understanding of immunology and inflammation through open scientific exchange. Additionally, Sanofi will provide funding and scientific inputs into projects of mutual interest, crossing multiple therapeutic areas including autoimmune diseases and inflammatory conditions. Sanofi and Stanford Medicine will create a Joint Steering Committee to fund up to three programs a year. Sanofi will host an annual research forum for researchers from both organizations to further exchange ideas, share knowledge and perspectives on relevant scientific matters, and discuss collaborative research projects. The collaboration will begin with three "deep-dive" research projects: exploring cytokine crosstalk in type 2 inflammation, specifically examining the impact of Sanofi's investigational molecules on excessive type 2 inflammation; decoding molecular drivers of effector and suppressor T cells in autoimmunity, to better understand the specific antigens that may cause type 1 diabetes and defining the mechanisms of immune-related adverse events with immune checkpoint inhibitor therapy - with a focus on pneumonitis and inflammatory arthritis - to explore the role of genomics and pathogenic cell identification.

05:16 EDT Aspen Aerogels files patent infringement lawsuit against AMA in Genoa - Aspen Aerogels announced that it has filed a patent infringement action at the Court of Genoa against AMA S.p.A. and AMA Composites S.r.l. related to the import and sale of aerogel products from China. Aspen collected evidence relevant to the case through a court-ordered search of AMA's premises. Aspen asserts that AMA infringes several of Aspen's patents, including those previously enforced successfully against Nano Hi-Tech Co. and Guangdong Alison in Germany. Aspen is seeking monetary damages and an injunction against AMA's allegedly infringing activities.

05:13 EDT UMC reports April sales of NT$ 16.38M, up 8.78%